Precise Insights

Advanced Data and AI for Renal Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo

 

labs

Results from variety of patient tests

Visits

Oncology practice visits

Observations

Tumor-related observations plus vitals, biometrics, pain, and more

Procedures

Surgeries, radiation, biopsies, imaging, chemotherapy, etc

Medications

Start and end dates, brand vs. generic codes, dosage, duration, and cycles

Diagnoses

Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo

 

Biomarkers

Biomarker testing, results, and timing

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses

Histology

Classification into multiple categories

Enriched Data

Request a Demo

 

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI-Enriched Insights

Request a Demo

 

Date of Metastasis

Rules-based imputation of date of metastasis

Metastatic Status

Imputation of missing data from unstructured notes

Date of Initial Dx

Imputation of index event

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

renal cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

renal cancer research study

Generalizability of Clinical Trials

Narrow trial eligibility criteria threatens generalizability of findings to real-world settings. This study compared patients receiving treatment for metastatic renal cell carcinoma (mRCC) to those enrolled in pivotal trials.

See Full Study
Methods

Retrospective Registry

Analysis
  • Community practices
  • Academic centers​
Patient Criteria
  • Registry patients were compared to trial subjects treated with the same agent
Results

633

Patients in registry

Findings:

0

Patients received sunitinib, sorafenib, temsirolimus, or pazopanib

The model improved accuracy:
0%

Had ECOG  >1


0%

Compared to trial population

Registry patients:

0

Years older than clinical trial subjects

0%

Failed to meet Phase III trial inclusion criteria

Conclusion

Real-world patients are older and sicker than those enrolled in pivotal clinical trials. Application of clinical trial findings to dissimilar populations may result in patient harm.

Research for Journal of Clinical Oncology, 2014

Request a Demo